Teleflex Highlights a Comparison of Eluting vs Non-Eluting Technologies on Peripherally Inserted Central Catheters (PICCs) in...
January 11 2016 - 6:30AM
Business Wire
Arrow® PICC with Chlorag+ard® Technology Shows
Greatest Reduction of Thrombus Formation when Compared to
Non-Eluting Antithrombogenic Technologies
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical devices for critical care and surgery, announces the
results of a pre-clinical intravascular study, highlighting Arrow®
PICC with Chlorag+ard® Technology and its ability to significantly
reduce thrombus formation when compared to competitive non-eluting
antithrombogenic technologies.
The pre-clinical study titled “Catheter Technologies: Is eluting
technology or non-eluting technology more effective in preventing
thrombus accumulation?” by Kamna Giare-Patel, MS, et al, evaluated
the effectiveness of three types of peripherally inserted central
venous catheters (PICCs) with antithrombogenic properties as
compared to uncoated PICCs in a clinically simulated ovine model.
The three test groups consisted of PICCs with fluorine-based
technology (AngioDynamics® BioFlo™ PICC with Endexo™ Technology),
chlorhexidine-based technology (Arrow® PICC with Chlorag+ard®
Technology) and Amphiphilic PMEA based technology (Terumo®
Xcoating™).
After 30 days, all catheters were explanted by dissecting the
vessels open. The amount of accumulated thrombus on the catheter
surfaces was measured for thrombus weight and length. Arrow® PICC
with Chlorag+ard® Technology showed the least amount of thrombus as
a result of greatest weight reduction (81%) and length reduction
(76%) when compared to the uncoated control catheter. Overall
results are in the table below:
FLUORINE- CHLORHEXIDINE-
PICC GROUP BASED BASED
PMEA-BASED
UNCOATED
(GROUP A) (GROUP B)
(GROUP C)
(GROUP D)
Technology Type Non-eluting Eluting
Non-eluting N/A Avg. Weight (g) 0.161 0.066
0.208 0.353 Avg. Length (cm) 4.2 1.7
3.0 7.0 % Weight Reduction (compared to control)
54% 81% 41% N/A % Length Reduction
(compared to control) 40% 76% 57% N/A
The authors of the poster concluded that the eluting technology
(Arrow® PICC with Chlorag+ard® Technology), compared to the two (2)
non-eluting technologies, showed the best outcomes by exhibiting
the most effective prevention of thrombus accumulation after a
30-day dwell time. The study was funded by, and authors are
employed by, Teleflex Incorporated.
Chlorag+ard® Technology treatment on the external surface of the
catheter body as well as the entire fluid pathway of the catheter
has been shown to be effective in reducing microbial colonization
and thrombus accumulation on catheter surfaces. The Arrow® PICC
with Chlorag+ard® Technology offers protection that is designed to
reduce the risk of catheter-related occlusion, thrombus
accumulation, intimal hyperplasia and catheter colonization for at
least thirty (30) days. Additional information may be found at
chloragard.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed
to improve the health and quality of people’s lives. We apply
purpose driven innovation – a relentless pursuit of identifying
unmet clinical needs – to benefit patients and healthcare
providers. Our portfolio is diverse, with solutions in the fields
of vascular and interventional access, surgical, anesthesia,
cardiac care, urology, emergency medicine and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®,
Pilling®, Rusch® and Weck® – trusted brands united by a common
sense of purpose.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Any forward-looking statements contained herein are
based on our management's current beliefs and expectations, but are
subject to a number of risks, uncertainties and changes in
circumstances, which may cause actual results or company actions to
differ materially from what is expressed or implied by these
statements. These risks and uncertainties are identified and
described in more detail in our filings with the Securities and
Exchange Commission, including our Annual Report on Form 10-K.
AngioDynamics, BioFlo and Endexo are trademarks or registered
trademarks of AngioDynamics, Inc.
Terumo and Xcoating are trademarks or registered trademarks of
Terumo Medical Corporation.
Teleflex, the Teleflex logo, Arrow, Deknatel, Hudson RCI, LMA,
Pilling, Rusch, Weck and Chlorag+ard are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries.
© 2016 Teleflex Incorporated. All rights reserved. MC-001893
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160111005005/en/
Teleflex IncorporatedJake ElguiczeTreasurer and Vice President,
Investor Relations610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Apr 2023 to Apr 2024